<p>Dyne Therapeutics, Inc.（纳斯达克代码：DYN - 获取免费报告）首席执行官约翰·考克斯在 5 月 13 日（星期三）出售了 3,311 股公司股票。股票的平均售价为 18.36 美元，总价值为 60,789.96 美元。交易后，首席执行官直接持有 370,834 股公司股票，估值约为 6,808,512.24 美元。此次交易使其持股比例减少了 0.88%。该出售在向证券交易委员会提交的文件中披露，相关文件可通过此链接访问。此次出售是为了覆盖与股权奖励归属相关的税款扣缴义务。</p>
<p>获取 <strong>Dyne Therapeutics</strong> 的最新提醒：</p>
<h2>Dyne Therapeutics 价格表现</h2>
<p>在周四的午盘交易中，纳斯达克 DYN 下跌 0.16 美元，报 18.28 美元。该股票的交易量为 913,113 股，而其平均交易量为 2,034,526 股。该公司的 50 日移动平均线为 18.22 美元，200 日移动平均线为 18.63 美元。Dyne Therapeutics, Inc.的 12 个月低点为 8.06 美元，12 个月高点为 25.00 美元。该公司的债务与股本比率为 0.17，流动比率为 19.92，速动比率为 22.25。该股票的市值为 30.2 亿美元，市盈率为-5.68，贝塔系数为 1.08。</p>
<p>Dyne Therapeutics（纳斯达克代码：DYN - 获取免费报告）最近在 5 月 11 日（星期一）发布了季度财报。公司报告本季度每股收益（EPS）为-0.73 美元，超出市场共识预期的-0.77 美元，超出幅度为 0.04 美元。去年同期，公司每股收益为-1.05 美元。股票研究分析师预测，Dyne Therapeutics, Inc.在当前财政年度的每股收益将为-2.97 美元。</p>
<h2>分析师评级升级与降级</h2>
<p>几位研究分析师最近对 DYN 股票发表了评论。Weiss Ratings 在 4 月 20 日（星期一）的研究报告中重新发布了对 Dyne Therapeutics 股票的 “卖出（d-）” 评级。HC Wainwright 将 Dyne Therapeutics 的目标价格从 60.00 美元下调至 50.00 美元，并在 3 月 3 日（星期二）的研究报告中给予该公司 “买入” 评级。Sanford C. Bernstein 在周三将 Dyne Therapeutics 的目标价格从 23.00 美元上调至 24.00 美元，并给予该股票 “市场表现” 评级。Chardan Capital 在 3 月 9 日（星期一）的研究报告中重申了 “买入” 评级，并对 Dyne Therapeutics 的股票设定了 38.00 美元的目标价格。最后，华尔街 Zen 在 5 月 2 日（星期六）的研究报告中将 Dyne Therapeutics 的评级从 “卖出” 下调至 “强烈卖出”。三位股票研究分析师给予该股票 “强烈买入” 评级，十一位给予 “买入” 评级，两位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat，该公司目前的共识评级为 “适度买入”，平均目标价格为 35.21 美元。</p>
<p><strong>阅读我们关于 DYN 的最新研究报告</strong></p>
<h2>Dyne Therapeutics 新闻摘要</h2>
<p>以下是本周影响 Dyne Therapeutics 的主要新闻：</p>
<ul>
<li>积极情绪：Lifesci Capital 上调了对 Dyne Therapeutics 2026 年第二、第三和第四季度每股收益的预期，暗示近期表现略有改善。Dyne Therapeutics 分析师预期更新</li>
<li>积极情绪：HC Wainwright 也上调了对 Dyne Therapeutics 2026 年第二、第三季度及全年每股收益的预期，并维持 “买入” 评级，目标价格为 50 美元，强化了长期看涨的前景。Dyne Therapeutics 分析师预期更新</li>
<li>中性情绪：Dyne Therapeutics 表示管理层将参加即将举行的投资者会议，这使公司在市场上保持可见性，但本身并未改变基本面。Dyne Therapeutics 将参加即将举行的投资者会议</li>
<li>消极情绪：并非所有长期预期都有所改善：HC Wainwright 下调了对 2027 年、2028 年、2029 年和 2030 年每股收益的预测，这可能会抑制对公司长期盈利前景的热情。Dyne Therapeutics 分析师预期更新</li>
</ul>
<h2>Dyne Therapeutics 的机构交易</h2>
<p>一些对冲基金和其他机构投资者最近修改了对 DYN 的持股。T. Rowe Price Investment Management Inc.在第四季度将其在 Dyne Therapeutics 的股份增加了 523.7%。T. Rowe Price Investment Management Inc.目前持有 17,540,089 股公司股票，价值 343,085,000 美元，此前在上个季度增持了 14,727,667 股。Orbis Allan Gray Ltd 在第四季度购买了 Dyne Therapeutics 的新头寸，价值 93,926,000 美元。Adage Capital Partners GP L.L.C.在第二季度购买了 Dyne Therapeutics 的新头寸，价值 30,378,000 美元。Perceptive Advisors LLC 在第四季度将其在 Dyne Therapeutics 的持股增加了 543.7%。Perceptive Advisors LLC 目前持有 3,478,944 股公司股票，价值 68,048,000 美元，此前在此期间增持了 2,938,500 股。最后，Marshall Wace LLP 在第三季度将其在 Dyne Therapeutics 的持股增加了 572.9%。Marshall Wace LLP 目前持有 3,013,377 股公司股票，价值 38,119,000 美元，此前在此期间增持了 2,565,570 股。96.68% 的股票由机构投资者和对冲基金持有。</p>
<h2>Dyne Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Dyne Therapeutics 是一家临床阶段的生物技术公司，专注于开发针对严重罕见疾病的局部基因调控疗法。公司的专有 FORCE（促进的正交受体介导的货物评估）平台旨在实现对寡核苷酸和基因治疗方式的靶向递送，主要针对骨骼和呼吸肌肉。Dyne 的主要项目集中在杜氏肌营养不良症（DMD）、肌强直性营养不良症 1 型（DM1）和面肩肱肌营养不良症（FSHD），目前正在进行安全性、耐受性和组织特异性的临床前和早期临床研究。</p>
<p>自 2019 年由 Flagship Pioneering 创立以来，Dyne 利用其模块化递送方法推进了多个产品候选药物，该方法将工程化配体与治疗性载荷结合，以改善肌肉细胞的摄取。</p>
<h2>另见</h2>
<ul>
<li>五只我们认为比 Dyne Therapeutics 更好的股票</li>
<li>YETI 在财报超预期和上调前景后反弹</li>
<li>三家领先的量子公司在第一季度财报后的对比</li>
<li>思科的垂直反弹可能仍处于早期阶段</li>
<li>亚马逊与阿里巴巴：现在显然一个是更好的价值投资</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFlO?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFlO"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Dyne Therapeutics 吗？</h2>
<p>在考虑 Dyne Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Dyne Therapeutics 并不在名单上。</p>
<p>虽然 Dyne Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

动态生物技术与基因组 ETF - Invesco

纳斯达克生物科技指数 ETF - iShares Nasdaq

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 3 倍做多 - Direxion

生物科技 ETF - VanEck Vectors

基因改革 ETF - ARK

标普生物技术 ETF - SPDR

2 倍做多纳斯达克生物技术 ETF - ProShares

医药突破 ETF - ALPS

<p>Dyne Therapeutics 首席执行官 John Cox 出售了 3,311 股，每股售价为 18.36 美元，总计 60,789.96 美元，以支付股权奖励的税务义务。出售后，他持有 370,834 股，价值约 680 万美元，持股比例下降了 0.88%。该股票目前交易价格为 18.28 美元，市值为 30.2 亿美元。分析师对 DYN 的评级褒贬不一，普遍共识为 “适度买入”，平均目标价为 35.21 美元。最近一些分析师上调了每股收益的预期，而另一些则下调了长期预测</p>

<p>Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) CEO John Cox sold 3,311 shares of the company's stock in a transaction that occurred on Wednesday, May 13th. The stock was sold at an average price of $18.36, for a total value of $60,789.96. Following the transaction, the chief executive officer directly owned 370,834 shares of the company's stock, valued at approximately $6,808,512.24. The trade was a 0.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.</p>
<div class="lb-trans"><p>Dyne Therapeutics, Inc.（纳斯达克代码：DYN - 获取免费报告）首席执行官约翰·考克斯在 5 月 13 日（星期三）出售了 3,311 股公司股票。股票的平均售价为 18.36 美元，总价值为 60,789.96 美元。交易后，首席执行官直接持有 370,834 股公司股票，估值约为 6,808,512.24 美元。此次交易使其持股比例减少了 0.88%。该出售在向证券交易委员会提交的文件中披露，相关文件可通过此链接访问。此次出售是为了覆盖与股权奖励归属相关的税款扣缴义务。</p>
</div><p>Get <strong>Dyne Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Dyne Therapeutics</strong> 的最新提醒：</p>
</div><h2>Dyne Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Dyne Therapeutics 价格表现</h2>
</div><p>NASDAQ DYN traded down $0.16 during mid-day trading on Thursday, hitting $18.28. The stock had a trading volume of 913,113 shares, compared to its average volume of 2,034,526. The firm's 50 day moving average is $18.22 and its 200 day moving average is $18.63. Dyne Therapeutics, Inc. has a twelve month low of $8.06 and a twelve month high of $25.00. The company has a debt-to-equity ratio of 0.17, a current ratio of 19.92 and a quick ratio of 22.25. The stock has a market capitalization of $3.02 billion, a price-to-earnings ratio of -5.68 and a beta of 1.08.</p>
<div class="lb-trans"><p>在周四的午盘交易中，纳斯达克 DYN 下跌 0.16 美元，报 18.28 美元。该股票的交易量为 913,113 股，而其平均交易量为 2,034,526 股。该公司的 50 日移动平均线为 18.22 美元，200 日移动平均线为 18.63 美元。Dyne Therapeutics, Inc.的 12 个月低点为 8.06 美元，12 个月高点为 25.00 美元。该公司的债务与股本比率为 0.17，流动比率为 19.92，速动比率为 22.25。该股票的市值为 30.2 亿美元，市盈率为-5.68，贝塔系数为 1.08。</p>
</div><p>Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.73) EPS for the quarter, beating the consensus estimate of ($0.77) by $0.04. During the same period last year, the company earned ($1.05) earnings per share. Equities research analysts forecast that Dyne Therapeutics, Inc. will post -2.97 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Dyne Therapeutics（纳斯达克代码：DYN - 获取免费报告）最近在 5 月 11 日（星期一）发布了季度财报。公司报告本季度每股收益（EPS）为-0.73 美元，超出市场共识预期的-0.77 美元，超出幅度为 0.04 美元。去年同期，公司每股收益为-1.05 美元。股票研究分析师预测，Dyne Therapeutics, Inc.在当前财政年度的每股收益将为-2.97 美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级升级与降级</h2>
</div><p>Several research analysts recently commented on DYN shares. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Dyne Therapeutics in a research note on Monday, April 20th. HC Wainwright cut their target price on Dyne Therapeutics from $60.00 to $50.00 and set a &#34;buy&#34; rating for the company in a research note on Tuesday, March 3rd. Sanford C. Bernstein raised their target price on Dyne Therapeutics from $23.00 to $24.00 and gave the stock a &#34;market perform&#34; rating in a research note on Wednesday. Chardan Capital reaffirmed a &#34;buy&#34; rating and issued a $38.00 target price on shares of Dyne Therapeutics in a research note on Monday, March 9th. Finally, Wall Street Zen downgraded Dyne Therapeutics from a &#34;sell&#34; rating to a &#34;strong sell&#34; rating in a research note on Saturday, May 2nd. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $35.21.</p>
<div class="lb-trans"><p>几位研究分析师最近对 DYN 股票发表了评论。Weiss Ratings 在 4 月 20 日（星期一）的研究报告中重新发布了对 Dyne Therapeutics 股票的 “卖出（d-）” 评级。HC Wainwright 将 Dyne Therapeutics 的目标价格从 60.00 美元下调至 50.00 美元，并在 3 月 3 日（星期二）的研究报告中给予该公司 “买入” 评级。Sanford C. Bernstein 在周三将 Dyne Therapeutics 的目标价格从 23.00 美元上调至 24.00 美元，并给予该股票 “市场表现” 评级。Chardan Capital 在 3 月 9 日（星期一）的研究报告中重申了 “买入” 评级，并对 Dyne Therapeutics 的股票设定了 38.00 美元的目标价格。最后，华尔街 Zen 在 5 月 2 日（星期六）的研究报告中将 Dyne Therapeutics 的评级从 “卖出” 下调至 “强烈卖出”。三位股票研究分析师给予该股票 “强烈买入” 评级，十一位给予 “买入” 评级，两位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat，该公司目前的共识评级为 “适度买入”，平均目标价格为 35.21 美元。</p>
</div><p><strong>Read Our Latest Research Report on DYN</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 DYN 的最新研究报告</strong></p>
</div><h2>Dyne Therapeutics News Summary</h2>
<div class="lb-trans"><h2>Dyne Therapeutics 新闻摘要</h2>
</div><p>Here are the key news stories impacting Dyne Therapeutics this week:</p>
<div class="lb-trans"><p>以下是本周影响 Dyne Therapeutics 的主要新闻：</p>
</div><ul>
<li>Positive Sentiment: Lifesci Capital raised its Q2, Q3 and Q4 2026 EPS estimates for Dyne Therapeutics, suggesting slightly better expected performance in the near term. Dyne Therapeutics analyst estimate updates</li>
<li>Positive Sentiment: HC Wainwright also lifted its Q2, Q3 and FY2026 EPS estimates and maintained a <strong>Buy</strong> rating with a <strong>$50</strong> price target, reinforcing a bullish longer-term outlook. Dyne Therapeutics analyst estimate updates</li>
<li>Neutral Sentiment: Dyne Therapeutics said management will participate in upcoming investor conferences, which keeps the company visible to the market but does not by itself change fundamentals. Dyne Therapeutics to Participate in Upcoming Investor Conferences</li>
<li>Negative Sentiment: Not all longer-dated estimates improved: HC Wainwright cut its FY2027, FY2028, FY2029 and FY2030 EPS forecasts, which may temper enthusiasm around the company’s longer-term profitability outlook. Dyne Therapeutics analyst estimate updates</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：Lifesci Capital 上调了对 Dyne Therapeutics 2026 年第二、第三和第四季度每股收益的预期，暗示近期表现略有改善。Dyne Therapeutics 分析师预期更新</li>
<li>积极情绪：HC Wainwright 也上调了对 Dyne Therapeutics 2026 年第二、第三季度及全年每股收益的预期，并维持 “买入” 评级，目标价格为 50 美元，强化了长期看涨的前景。Dyne Therapeutics 分析师预期更新</li>
<li>中性情绪：Dyne Therapeutics 表示管理层将参加即将举行的投资者会议，这使公司在市场上保持可见性，但本身并未改变基本面。Dyne Therapeutics 将参加即将举行的投资者会议</li>
<li>消极情绪：并非所有长期预期都有所改善：HC Wainwright 下调了对 2027 年、2028 年、2029 年和 2030 年每股收益的预测，这可能会抑制对公司长期盈利前景的热情。Dyne Therapeutics 分析师预期更新</li>
</ul>
</div><h2>Institutional Trading of Dyne Therapeutics</h2>
<div class="lb-trans"><h2>Dyne Therapeutics 的机构交易</h2>
</div><p>A number of hedge funds and other institutional investors have recently modified their holdings of DYN. T. Rowe Price Investment Management Inc. increased its stake in shares of Dyne Therapeutics by 523.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company's stock worth $343,085,000 after acquiring an additional 14,727,667 shares during the last quarter. Orbis Allan Gray Ltd purchased a new position in shares of Dyne Therapeutics during the 4th quarter worth $93,926,000. Adage Capital Partners GP L.L.C. purchased a new position in shares of Dyne Therapeutics during the 2nd quarter worth $30,378,000. Perceptive Advisors LLC grew its holdings in shares of Dyne Therapeutics by 543.7% during the 4th quarter. Perceptive Advisors LLC now owns 3,478,944 shares of the company's stock worth $68,048,000 after purchasing an additional 2,938,500 shares during the period. Finally, Marshall Wace LLP grew its holdings in shares of Dyne Therapeutics by 572.9% during the 3rd quarter. Marshall Wace LLP now owns 3,013,377 shares of the company's stock worth $38,119,000 after purchasing an additional 2,565,570 shares during the period. 96.68% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近修改了对 DYN 的持股。T. Rowe Price Investment Management Inc.在第四季度将其在 Dyne Therapeutics 的股份增加了 523.7%。T. Rowe Price Investment Management Inc.目前持有 17,540,089 股公司股票，价值 343,085,000 美元，此前在上个季度增持了 14,727,667 股。Orbis Allan Gray Ltd 在第四季度购买了 Dyne Therapeutics 的新头寸，价值 93,926,000 美元。Adage Capital Partners GP L.L.C.在第二季度购买了 Dyne Therapeutics 的新头寸，价值 30,378,000 美元。Perceptive Advisors LLC 在第四季度将其在 Dyne Therapeutics 的持股增加了 543.7%。Perceptive Advisors LLC 目前持有 3,478,944 股公司股票，价值 68,048,000 美元，此前在此期间增持了 2,938,500 股。最后，Marshall Wace LLP 在第三季度将其在 Dyne Therapeutics 的持股增加了 572.9%。Marshall Wace LLP 目前持有 3,013,377 股公司股票，价值 38,119,000 美元，此前在此期间增持了 2,565,570 股。96.68% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Dyne Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Dyne Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.</p>
<div class="lb-trans"><p>Dyne Therapeutics 是一家临床阶段的生物技术公司，专注于开发针对严重罕见疾病的局部基因调控疗法。公司的专有 FORCE（促进的正交受体介导的货物评估）平台旨在实现对寡核苷酸和基因治疗方式的靶向递送，主要针对骨骼和呼吸肌肉。Dyne 的主要项目集中在杜氏肌营养不良症（DMD）、肌强直性营养不良症 1 型（DM1）和面肩肱肌营养不良症（FSHD），目前正在进行安全性、耐受性和组织特异性的临床前和早期临床研究。</p>
</div><p>Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.</p>
<div class="lb-trans"><p>自 2019 年由 Flagship Pioneering 创立以来，Dyne 利用其模块化递送方法推进了多个产品候选药物，该方法将工程化配体与治疗性载荷结合，以改善肌肉细胞的摄取。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Dyne Therapeutics</li>
<li>YETI Rallies After Earnings Beat and Raised Outlook</li>
<li>How the 3 Leading Quantum Firms Stack Up After Q1 Earnings</li>
<li>Cisco’s Vertical Rally May Still Be in the Early Innings</li>
<li>Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Dyne Therapeutics 更好的股票</li>
<li>YETI 在财报超预期和上调前景后反弹</li>
<li>三家领先的量子公司在第一季度财报后的对比</li>
<li>思科的垂直反弹可能仍处于早期阶段</li>
<li>亚马逊与阿里巴巴：现在显然一个是更好的价值投资</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFlO" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=DYN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Dyne Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Dyne Therapeutics 吗？</h2>
</div><p>Before you consider Dyne Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Dyne Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dyne Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Dyne Therapeutics 并不在名单上。</p>
</div><p>While Dyne Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Dyne Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Dyne Therapeutics (NASDAQ:DYN) CEO John Cox Sells 3,311 Shares

Market Beat

Dyne Therapeutics

普信金融

Dyne Therapeutics（纳斯达克代码：DYN）的首席执行官 John Cox 出售了 3,311 股股票